Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vaginal inflammation21.14.02.001--
Vertigo17.02.12.002; 04.04.01.0030.003476%
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.005793%
Visual impairment06.02.06.0080.003476%Not Available
Vitiligo23.05.02.004; 10.04.02.0040.008110%Not Available
Vomiting07.01.07.003--
Vulval disorder21.08.01.007--Not Available
Vulvitis21.14.02.006; 11.01.10.007--
Weight decreased13.15.01.0050.003476%
White blood cell count13.01.06.027--Not Available
White blood cell count decreased13.01.06.012--
Application site vesicles08.02.01.009; 23.03.01.009; 12.07.01.009--Not Available
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.011--Not Available
Application site inflammation12.07.01.024; 08.02.01.024--Not Available
Application site papules08.02.01.025; 23.03.03.022; 12.07.01.025--Not Available
Lip blister23.03.01.016; 07.05.01.0070.003476%Not Available
Excoriation23.03.11.003; 12.01.06.007--Not Available
Balance disorder17.02.02.0070.002317%Not Available
Application site hyperaesthesia17.02.06.011; 12.07.01.023; 08.02.01.023--Not Available
Application site paraesthesia08.02.01.026; 17.02.06.012; 12.07.01.026--Not Available
Lupus-like syndrome15.06.02.004; 10.04.03.003; 23.03.02.0040.008110%Not Available
Malignant neoplasm progression16.16.01.0050.000604%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Conjunctival hyperaemia06.04.01.0040.004634%Not Available
Skin induration23.03.03.0200.002317%
Eye pruritus06.04.05.0060.005793%Not Available
Application site discharge23.03.03.049; 12.07.01.039; 08.02.01.039--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Lymphatic disorder01.09.01.003--Not Available
The 9th Page    First    Pre   9 10 11 12    Next   Last    Total 12 Pages